METTL3 and lung adenocarcinoma: DUXAP8 sponges miR‐584‐5p to upregulate MAPK1 resulting in resistance to sorafenib.[114] METTL3 contributed to erlotinib resistance in lung adenocarcinoma through eliminating suppression of Notch signaling by TUSC7.